MedChemExpress LLC’s Post

Another exciting acquisition in the space with Repligen Corporation acquiring Tantti Laboratory Inc.! Repligen, a bioprocessing leader, announced yesterday bioprocessing technology leadership that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics. Tony J. Hunt, Chief Executive Officer at Repligen said, “The addition of Tantti further strengthens our portfolio in the new modality space. Combining Tantti’s innovative bead technology with the content we are generating from Avitide will be game-changing. The industry needs high throughput and high-capacity purification products, and Tantti is the solution to delivering on this. We are excited to welcome the Tantti team to Repligen, and we look forward to further developing and integrating their differentiated technology into our portfolio.” Joe Yang, Chief Executive Officer at Tantti said, “We have been working with Repligen for a few years now and we are thrilled to combine the power of Tantti’s bead technology with the capabilities of Avitide and to leverage the commercial strength of Repligen to make DuloCore the gold-standard in the marketplace for new modality purification. Repligen is the ideal partner for us to take this next step of growth and we look forward to working with our colleagues at Repligen to accelerate our market presence in bioprocessing.” #acquisition #bioprocess #chromatography

#ACROHighlights [Featured Product] 🔬 TL1A-DR3 (TR-FRET) Kit: Advancing TL1A Drug Discovery The TL1A-DR3 Inhibition Kit (TR-FRET) by ACROBiosystems is revolutionizing inhibitor screening with its high sensitivity, specificity, and ease of use. Leveraging Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology ensures accurate detection of biomolecular interactions by reducing background interference. This kit is a reliable tool for TL1A-DR3 drug discovery, offering repeatable and efficient results. ➡️ Learn more about TL1A products here: https://smpl.is/9v6f9 #TRFRET #TL1A #DrugDiscovery #BiotechInnovation #InhibitorScreening #HighThroughputAssays

Incredible Advances in Drug Discovery!   We’re following with great interest the exciting developments in targeted therapies, especially the work Recludix Pharma is doing with STAT proteins. Their approach of inhibiting SH2 domains of STAT3 and STAT6 promises to open new doors in selective and highly effective treatments, which could potentially reduce side effects and improve patient outcomes, particularly in challenging therapeutic areas like cancer.    Targeting individual STAT proteins is a unique way to approach this class of pathways and may redefine how we think about JAK/STAT modulation. Kudos to the team at Recludix Pharma for their pioneering efforts in the drug discovery landscape.   #DrugDiscovery #STATInhibitors #OncologyInnovation  #PharmaInnovation #BiotechBreakthroughs #RecludixPharma

Drug #permeation studies using #μFlux showed that the size of the drug-rich phase formed by LLPS strongly affects the #membrane #permeability of the #drug. https://lnkd.in/eSWHvad9 #drugdelivery #drugdevelopment

𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀! 😃 LabSolutions Insight Biologics is a software for analyzing the characteristics of #oligonucleotides using either single quadrupole (SQ) Mass Spectrometers, quadrupole time-of-flight (QTOF) MS, or #MALDI MS. Analyzing the characteristics of oligonucleotides involves the identification of #impurities and sequence confirmation with modification positions estimated. ✅ LCMS SQ ✅ LCMS QTOF ✅ MALDI 👉 https://lnkd.in/eG6W8W2S #oligos #therapeutics #cdmo #drugdevelopment

Developing and screening plasmid libraries is critical to biotherapeutic development. Maintaining plasmid libraries and preventing evolution is essential for consistent manufacturing. Learn how Danaher Life Sciences can help: https://bit.ly/4d3eHw8 #DanaherLifeSciences #pDNA #plasmid #drugdiscovery #drugdevelopment

Join us for this week's 🔓AMS Unlocked with Azza Halim, MD, as we delve into biologics for advanced laser rejuvenation and anti-aging. Discover the mechanism of action (MOA) of exosomes, strategies to amplify laser efficacy, and synergistic approaches for the best possible results. 🔗Watch the video now - https://lnkd.in/eG2bv5jF #AestheticEducation #AestheticMedicine #MedicalAesthetics #AMS

R&D and Manufacturing of GGFG linker and exatecan faced two challenging issues in the ADC drug production, which should produce irreversible effects on the preclinical study and clinical study. First issue is racemization of the F amino acid during the peptide coupling significantly impacting on the release efficiency of payload. Another problem is the dr value of Exatecan coming from the chemical suppliers or CROs, which shall reduce the efficacy of ADC drug in the clinical study. Synmolecules CO.,LTD focuses on the ADC drug R&D and successfully solves those problems. Please feel free to contact us if you have any questions. synmolecules@163.com

🔔 Taking part in the 9th RSC-BMCS Fragment-based Drug Discovery Meeting in Cambridge today and tomorrow? Stop by booth number 15 to speak with our NUVISAN experts Krzysztof Brzezinka and Martina Schaefer. 📅 In addition, don't miss Martina's presentation tomorrow at 11:30. She will present on the topic: Discovery of potent SOS1 inhibitors through complementary use of FBDD and HTS with insightful discussion to follow! #highthroughput #fragment #screening #KRAS #drugdiscovery

Learn how #FlagshipFounded Abiologics is unlocking the next generation of biologics called Synteins™, a new biotherapeutic class with supranatural properties, revealing a world of new possibilities for patients. Jaclyn Dunphy and Mike Hamill explain how advances in generative protein design and optimization paired with automated chemical peptide synthesis are enabling this new approach to programmable biotherapeutics. Read more: https://bit.ly/4fy3sNf